China-based Meinian Onehealth Healthcare (Group) Co., Ltd (SHE: 002044) has entered into a partnership with compatriot firm Astra Biotechnology Co., Ltd to develop hypersensitive blood biomarker detection capabilities. The collaboration will focus on creating a humoral biomarker detection scheme and screening model for physical examinations targeting brain diseases and other conditions, as well as promoting the product in the market and related educational activities. No financial details were disclosed.
Development Goals
Under the agreement, the two companies will develop physical examination items and a risk assessment model for hypersensitive blood biomarkers using single-molecule immune technology. Meinian will file for marketing approval and provide single-molecule immune detection and molecular detection services based on blood samples for people of different ages at its physical examination centers.
Technical Support and Implementation
Astra Biotechnology will provide relevant single-molecule platform technical support to facilitate the implementation of the humoral biomarker detection schemes and screening models. This partnership aims to enhance the accuracy and efficiency of physical examinations, particularly in detecting early signs of brain health issues and other diseases.
Significance of the Partnership
This collaboration is expected to significantly advance the capabilities of physical examinations by incorporating advanced biomarker detection technologies. By combining their expertise, Meinian Onehealth and Astra Biotechnology aim to improve early diagnosis and risk assessment for various health conditions, ultimately enhancing overall healthcare outcomes.-Fineline Info & Tech
